
Do CAR-NK cells made in the body treat cancer?
Checked
Posts say that CAR-NK cells made inside the body, rather than in a lab, can treat cancer.
There is no reliable scientific evidence that CAR-NK cells made in the body treat cancer. It has been tested in animals or on cells in the lab, but we found no study of it in people.
What studies show
As of , no study in people shows that CAR-NK cells made in the body treat cancer. We found 7 published papers on CAR-NK cells made in the body and cancer. They were published between 2023 and 2026. From their records, none of them is a study in people. 1 was a study in animals, and 1 was only in cells in the lab.
In animals
A 2026 mouse study used tiny fat particles to change a mouse's own immune cells inside its body. The best particles reached up to about 80% of these immune cells. The authors adapted the particles for human cells. Two blood cancers in mice then shrank.
In the lab
A 2025 test in dishes used immune cells changed outside the body. These cells killed cancer cells in the dishes. This is not the same as making the cells inside the body.
What this means for you
Our verdict: Unproven.
So far, in-body CAR-NK cells have only been shown in mice. Results in animals do not always hold in people.
Do not stop or change your treatment because of a story about CAR-NK cells made in the body. Results in animals or in cells often do not hold in people. If you are thinking about CAR-NK cells made in the body, talk to your care team first.
This page explains what research has found so far. It is not medical advice. Talk to your doctor before you start, stop or change any treatment.
We searched 18 scientific databases for research from the last 10 years (since 2016. nov. 17.).
Sources
- In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles. Nat Biotechnol 2026. In animals. PubMed
- Engineering Natural Killer Cells for Cancer Immunotherapy: Advances, Challenges, and Future Perspectives. Premier Journal of Immunology 2026. Other paper. Premier Journal of Immunology
- Synthesis of mRNA lipid nanoparticles for engineering GD2 CAR T and CAR NK cells against neuroblastoma. bioRxiv 2025. In the lab. PubMed
- Chimeric Antigen Cytotoxic Receptors for In-Vivo Engineering of Tumor-targeting Natural Killer Cells. bioRxiv 2023. Other paper. bioRxiv



